Fusion Pharmaceuticals Inc (FUSN) has released an update.
Fusion Pharmaceuticals Inc. has revealed promising interim data for its prostate cancer treatment, FPI-2265, and is preparing for Phase 2 and 3 trials. Concurrently, the company is set to be acquired by AstraZeneca for up to $2.4 billion, with the transaction likely to conclude in Q2 2024. The deal includes a base purchase price and a contingent value right subject to regulatory milestones.
For further insights into FUSN stock, check out TipRanks’ Stock Analysis page.
